Home ›
Trademark Categories ›
Pharmaceuticals ›
2009 ›
PE ›
PEPVIDA
Trademark search for:
PEPVIDA
No active United States Patent and Trademark Office (USPTO) registrations found, based on publicly available USPTO trademark records.
Trademark records may change over time.
For the most up-to-date trademark status, domain availability,
and social handle checks, run a live search.
Check latest trademark, domains & social handles
Live search · Most up-to-date results
USPTO Filing History
Key events recorded for this trademark application
2009-01-15 — Application filed
2009-01-21 — Application filed
2009-02-20 — Assigned to examiner
2009-03-03 — Final disposition recorded
2009-03-03 — Final disposition recorded
2009-03-03 — Final disposition recorded
2009-04-03 — Final disposition recorded
2009-04-03 — Final disposition recorded
2009-04-03 — Final disposition recorded
2009-04-23 — Office action issued
2009-04-25 — Assigned to lie
2009-04-27 — Teas/email correspondence entered
2009-04-27 — Correspondence received in law office
2009-05-16 — Examiners amendment -written
2009-05-16 — Examiners amendment e-mailed
2009-05-16 — Notification of examiners amendment e-mailed
2009-05-16 — Examiner's amendment entered
2009-05-27 — Approved for pub - principal register
2009-06-10 — Law office publication review completed
2009-06-24 — Notice of publication
2009-07-14 — Published for opposition
2009-08-13 — Extension of time to oppose received
2009-11-27 — Extension of time to oppose process - terminated
2010-01-05 — Registered-principal register
2016-08-12 — Cancelled sec. 8 (6-yr)
2016-08-12 — Final status recorded
Owner Information
DSM IP Assets B.V.
Heerlen NL
DSM IP Assets B.V.
Heerlen NL
DSM IP Assets B.V.
Heerlen NL
Correspondent
DUANE M. BYERS NIXON & VANDERHYE 901 N GLEBE RD STE 1100 ARLINGTON, VA 22203-4184 UNITED STATES
Filing Details
Filing Date:
2009-01-15
Status Date:
2016-08-12
Disclaimer: This page is informational only and does not constitute legal advice.
Trademark availability depends on jurisdiction, usage, and legal interpretation.